Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination chemotherapy regimen consisting of three agents: - **Hexamethylmelamine (also known as altretamine):** An oral alkylating agent that damages DNA, leading to inhibition of cancer cell growth and cell death. It is primarily used in ovarian cancer and has been studied in various combinations for other malignancies[6][8][9]. - **Doxorubicin:** An anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals, resulting in cytotoxicity. It is widely used for a variety of cancers. - **Vincristine:** A vinca alkaloid that binds to tubulin and inhibits microtubule formation, arresting cells in metaphase during mitosis. This specific combination has been investigated as part of multi-drug regimens for advanced cancers such as ovarian cancer and small-cell lung cancer[2][3]. The rationale behind combining these drugs is to exploit their different mechanisms of action for synergistic antitumor effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hexamethylmelamine + doxorubicin + vincristine.